

MedTech Catapult and CRIS Partner to Advance Clinical Validation and Market Readiness of MedTech Innovations



(L to R): Ms Irene Cheong, Assistant Chief Executive, Innovation & Enterprise, A*STAR;
A/Prof Danny Soon, Chief Executive Officer, CRIS

Photo courtesy of the CRIS

On 25 August 2025, **MedTech Catapult (MC)** and the **Consortium for Clinical Research and Innovation, Singapore (CRIS)** have signed a Memorandum of Understanding (MOU) to enhance Singapore's MedTech ecosystem by bridging product development with robust clinical validation and trial design.

This partnership underscores MC's commitment to work more closely with the clinical community, complementing its recent collaborations with ClavystBio, Fogarty Innovation, and Lightstone Ventures. While those partnerships focused on productisation and fundraising, the new MOU with CRIS adds a critical pillar of support in clinical validation which is an essential step in preparing high-value medical technologies for market adoption.

Through the partnership, MC and CRIS will collaborate to:

- Connect innovators with clinical partners and trial sites to accelerate validation efforts.
- Support tailored trial design, health economic assessments, and early HealthTech evaluation to strengthen evidence generation.
- Provide co-funding and strategic resources for selected projects.

"This MOU represents a major step in aligning product development with the clinical evidence needed for adoption in healthcare systems worldwide," said **Ms Irene Cheong, Assistant Chief Executive, Innovation & Enterprise, A*STAR**. "By bringing together CRIS's clinical trial and innovation expertise with MC's productisation and venture acceleration capabilities, we are equipping innovators with an integrated pathway from bench to bedside."

A/Prof Danny Soon, CEO of CRIS, added, "Our collaboration with MedTech Catapult reinforces Singapore's position as a trusted hub for MedTech innovation. By leveraging CRIS's clinical trial networks, health innovation expertise, and strategic healthcare partnerships, we aim to accelerate the development of transformative medical technologies that improve patient outcomes."

The event also featured a regulatory sharing session by the Health Sciences Authority (HSA) on evolving frameworks for AI-enabled medical devices, underscoring the importance of bringing innovators, healthcare systems, and regulators together to advance safe and effective adoption. This reflects emerging growth opportunities in AI-connected smart devices, a key area driving the next wave of MedTech innovation.

About MedTech Catapult: *MedTech Catapult is a national initiative to accelerate the productisation and commercialisation of Medical Technologies. It provides innovators with dedicated support to bring their products from concept to market, connecting them with clinical partners, contract manufacturers, and global venture networks.*

About CRIS: *The Consortium for Clinical Research and Innovation, Singapore (CRIS) is a national platform that advances clinical research and innovation through its business units including the Singapore Clinical Research Institute (SCRI) and the National Health Innovation Centre Singapore (NHIC). CRIS supports clinical development, trial design, and innovation adoption to strengthen Singapore's biomedical ecosystem.*